OUR NAME IS NEW.
OUR COMMITMENT TO HEALTHCARE WILL NEED NO INTRODUCTION.

Few enterprises arrive in the world as ready to serve patients as AbbVie. We are a new biopharmaceutical company, emerging from Abbott with a 125-year history of patient care.

To advance global healthcare, AbbVie unites the expertise and stability of a successful pharmaceutical company with the innovative scientific spirit of a biotech. Our commitment to deliver solutions that make a remarkable impact in people’s lives continues the legacy of our Abbott origins.

We’re proud to introduce ourselves as AbbVie, but we never forget that what we do is more important than what we’re named.

AbbVie.com
Dear Colleague,

We are pleased to welcome you at the **4th International Workshop on HIV & Women, from Adolescence through Menopause**, in the Westin Georgetown hotel in Washington DC.

Women and HIV is a very complex field of research. Whereas there are many conferences worldwide to discuss the various aspects of HIV treatment, this conference is the only international platform where the specific aspects for treatment of HIV infected women are discussed. The fourth edition of the event will once again present a unique and much needed platform for international scientific exchange on the increasingly recognized problems of HIV and Women.

The workshop will gather a cross-disciplinary team of experts and trainees involved in research on HIV and Women, in order to present and discuss the latest developments and strategies for the future, in an interactive and science - focused setting.

The meeting will consist of a program with invited lectures, abstract-driven scientific presentations and poster sessions. The latest developments will be reviewed and evaluated in order to identify important topics for future research, develop better approaches to treatment, and create a strategic agenda for future management problems associated with HIV and Women.

We hope that you will enjoy the **4th International Workshop on HIV & Women**.

The Organizing Committee,

Dr Cate Hankins  
Dr Margaret Johnson  
Dr Angela Kashuba  
Dr Kate Squires  
Dr Sharon Walmsley
ACKNOWLEDGEMENT

This workshop has been made possible by our sponsors. Financial support for the 4th International Workshop on HIV & Women have been provided by the following companies:

GOLD LEVEL SPONSOR

Abbvie

SILVER LEVEL SPONSOR

Gilead Sciences

ViiV Healthcare

PRINCIPAL SUPPORTER

Janssen

ACADEMIC SUPPORTERS

Amsterdam Institute for Global Health and Development

Jefferson University Hospitals

University Health Network

Royal Free London NHS Foundation Trust

4th International Workshop on HIV & Women, 13 - 14 January 2014, Washington, DC, USA
CONTENT

PROGRAM - 4TH INTERNATIONAL WORKSHOP ON HIV & WOMEN

Welcome ........................................................................................................... p. 1
Acknowledgement .......................................................................................... p. 2
Organizing Committee .................................................................................... p. 4
Scientific Committee ....................................................................................... p. 5
General Information ........................................................................................ p. 5
Program ............................................................................................................ p. 6
Invited Speakers ................................................................................................ p. 9

ABSTRACTS - REVIEWS IN ANTIVIRAL THERAPY & INFECTIOUS DISEASES 2014_1

Abstracts – Oral presentations ......................................................................... p. 1
Abstracts – Poster presentations ..................................................................... p. 25
Author Index .................................................................................................... p. 53
Cate Hankins, MD

Dr. Catherine Hankins is Deputy Director, Science at the Amsterdam Institute for Global Health and Development, and an Honorary Professor at the London School of Hygiene and Tropical Medicine in the Faculty of Epidemiology and Population Health.

Margaret Johnson, MD, FRCP

Professor Margaret Johnson is the clinical director of the Royal Free Centre for HIV medicine and Professor of HIV Medicine at University College London.

Angela Kashuba, BScPhm, PharmD, DABCP

Dr Angela Kashuba is the John A. and Deborah S. McNeil Jr Distinguished Professor and Vice-Chair for Research and Graduate Education in the Div. of Pharmacotherapy and Experimental Therapeutics in the Eshelman School of Pharmacy, Director of the University of North Carolina Center for AIDS Research Clinical Pharmacology and Analytical Chemistry Core and Director of the UNC CARE Collaboratory for HIV Eradication Pharmacology Core.

Kate Squires, MD

Dr Kathleen E. Squires is Professor of Medicine at Jefferson Medical College and Director of the Division of Infectious Diseases at Thomas Jefferson University Hospital, Philadelphia, PA, USA.

Sharon Walmsley, FRCPC, MD, MSc

Dr. Sharon Walmsley is Director of Clinical Research, Immunodeficiency Clinic, Toronto Hospital, University Health Network and Professor at the University of Toronto, Department of Medicine, Canada.
SCIENTIFIC COMMITTEE

Quarraisha Abdool Karim, PhD  University of Kwazulu Natal, South Africa
Katherine Anastos, MD  Montefiore Medical Center, USA
Jean Anderson, MD  Johns Hopkins University, USA
Antonella d’Arminio Monforte, MD  University of Milan, Italy
Gina Brown, MD  NIH, Office for AIDS Research, USA
Cynthia Firnhaber, MD  University of the Witwatersrand, South Africa
Beatriz Grinsztejn, MD  Hospital Evandro Chagas, Brazil
Shirin Heidari, PhD  European Association of Science Editors, UK
Sharon Lewin, MD  Alfred Hospital, Australia
Mona Outfy, MD, FRCP, MPH  Women’s College Research Institute, Canada
Fiona Mulcahy, MD, FRCP  St. James’s Hospital, Ireland
Kristine Patterson, MD  University of North Carolina, USA
Natella Rakhmanina, MD, PhD  Children’s National Medical Center, USA
Jonathan Schapiro, MD  Sheba Medical Center, Israel
Annette Sohn, MD  TREAT Asia, Thailand
Aaron Tobian, MD, PhD  Johns Hopkins University, USA

GENERAL INFORMATION

Badge Policy
All registered delegates are provided with an identity badge. Please wear it at all times to ensure admission to the meeting.

Certificate of Attendance
A certificate of attendance can be picked up from the registration desk on Tuesday 14 January.

Date and Venue
The dates of the meeting are Monday 13 January – Tuesday 14 January 2014
The meeting is being held in the Westin Georgetown Hotel, Washington, DC, USA.

Language
The official language of the workshop is English.

Social Program (pre-registration required)
Monday 13 January: Workshop dinner

Workshop Secretariat
The registration desk is located in the pre-function area. The conference organizers can be addressed for all questions concerning the logistics of the meeting at all times.
# PROGRAM

## MONDAY 13 JANUARY

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30h</td>
<td>Opening of the Workshop</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:35h</td>
<td>Session 1</td>
<td>Prevention of Infection</td>
<td></td>
</tr>
<tr>
<td>08.35h</td>
<td>Invited Lecture: PrEP, gender issues</td>
<td>J. Anderson</td>
<td></td>
</tr>
<tr>
<td>09.05h</td>
<td>Adolescent and young women’s acceptability and use of a proxy microbicide gel or pill in a mock trial in Tanzania</td>
<td>J. Headley #1</td>
<td></td>
</tr>
<tr>
<td>09.20h</td>
<td>Characteristics associated with both adherence and sexual risk behaviors among women infected with HIV</td>
<td>S. Spangler #2</td>
<td></td>
</tr>
<tr>
<td>09.35h</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.00h</td>
<td>Invited Lecture: Cure: early detection and early treatment</td>
<td>M. Robb</td>
<td></td>
</tr>
<tr>
<td>10.05h</td>
<td>The inclusion (or exclusion) of women in HIV research: from clinical studies of ARVs and vaccines to cure strategies</td>
<td>S. Heidari #3</td>
<td></td>
</tr>
<tr>
<td>10.45h</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.15h</td>
<td>Coffee break &amp; posterviewing mini orals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.45h</td>
<td>Session 2</td>
<td>Models of Care</td>
<td></td>
</tr>
<tr>
<td>11.45h</td>
<td>Invited Lecture: The US situation</td>
<td>J. Kates</td>
<td></td>
</tr>
<tr>
<td>12.00h</td>
<td>Invited Lecture: The UK/European situation</td>
<td>M. Johnson</td>
<td></td>
</tr>
<tr>
<td>12.15h</td>
<td>Invited Lecture: The RLS situation</td>
<td>K. Naidoo</td>
<td></td>
</tr>
<tr>
<td>12.30h</td>
<td>Clinical characteristics and quality of HIV care for women in the United States: Data from the Medical Monitoring Project, 2009</td>
<td>W. Short #4</td>
<td></td>
</tr>
<tr>
<td>12.35h</td>
<td>Acceptability of a proposed technology-assisted, group-based intervention promoting engagement in care and treatment for HIV-infected women</td>
<td>O. Blackstock #5</td>
<td></td>
</tr>
<tr>
<td>12.40h</td>
<td>The Oak Tree Clinic: a model of women-centered HIV care in British Columbia</td>
<td>M. Kestler #6</td>
<td></td>
</tr>
<tr>
<td>12.45h</td>
<td>A conceptual model of trauma-informed primary care for women living with HIV</td>
<td>E. Machtinger #7</td>
<td></td>
</tr>
<tr>
<td>12.50h</td>
<td>Factors associated with missed clinic visits at a tertiary care centre</td>
<td>L. Szadkowski #8</td>
<td></td>
</tr>
<tr>
<td>12.55h</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.30h</td>
<td>Lunch</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.30h</td>
<td>Session 3</td>
<td>Conception and Contraception</td>
<td></td>
</tr>
<tr>
<td>14.30h</td>
<td>Invited Lecture: Conception and HIV</td>
<td>F. Lyons</td>
<td></td>
</tr>
<tr>
<td>15.00h</td>
<td>Patterns and predictors of dual contraceptive use among sexually active treatment experienced women living with HIV in British Columbia, Canada.</td>
<td>S. Patterson #9</td>
<td></td>
</tr>
<tr>
<td>15.15h</td>
<td>An economic evaluation of conception strategies for heterosexual serodiscordant couples with HIV-positive male partners</td>
<td>M. Letchumanan #10</td>
<td></td>
</tr>
</tbody>
</table>
PROGRAM

TUESDAY 14 JANUARY

Session 5 Comprehensive Management considerations for Women; Co-morbidities & Co-infections

08.30h Invited Lecture: HIV, oncogenic HPV and Prevention Methods
A. Tobian

09.00h Lower immune response in HIV positive girls to the qHPV vaccine
D. Money #15

09.15h Discussion

09.30h Invited Lecture: Osteoporosis in elderly HIV infected women
S. Cardew

10.00h Discussion

10.15h Coffee break & Guided Poster Viewing

Session 6 Comprehensive Management considerations for Women; Co-morbidities & Co-infections

11.00h Invited Lecture: Epidemiology of HCV co-infection
S. Mehta

11.30h Invited Lecture: New treatment options for HIV-Hepatitis C Co-infection
M. Klein

12.00h (Panel) Discussion

15.30h Understanding current contraceptive choices and patterns among a cohort of HIV-positive women
M. Sharma #11

15.45h Discussion

16.00h Coffee Break

Session 4 Pregnancy

16.30h Perceived stress in pregnancy and postpartum of mothers living with HIV in Ontario, Canada
A. Ion #12

16.45h High proportion of unintended pregnancies and limited contraceptive use among HIV-positive women in rural Zambia
N. Ishikawa #13

17.00h Increasing Numbers of Young Pregnant Women with HIV in a South African district
A. Grimwood #14

17.15h Discussion

17:30h Adjournment for the day
PROGRAM

TUESDAY 14 JANUARY

12.30h  Lunch

Session 7  State of ART in HIV-Infected Women

13.30h  Invited Lecture: State-of-the art lecture on new therapy options  
S. Walmsley

14.00h  Discussion

14.15h  Single-tablet regimen rilpivirine/emtricitabine/tenofovir DF is safe and well-tolerated to efavirenz/emtricitabine/tenofovir DF in art-naive females  
E. Elbert  #16

14.20h  The efficacy and safety of raltegravir in women  
K. Squires  #17

14.25h  Improved Virological Outcomes Amongst Women Starting Efavirenz for First-Line Antiretroviral Treatment In South Africa.  
A. Grimwood  #18

14.30h  HAART discontinuation in women: Results from the Chilean Aids Cohort  
P. Vasquez  #19

14.35h  Gender disparities in treatment based outcomes persist in the era of modern ART  
M. Johnson  #20

14.40h  Systematic review of clinical outcomes of infants born to women receiving lopinavir/ritonavir-based antiretroviral therapy (ART) during pregnancy  
M. Martinez  #21

14.45h  Morbidity among HIV exposed uninfected children compared to children not exposed to HIV – a danish nationwide study  
E. Moseholm Larsen  #22

14.50h  Discussion

15.00h  Closure of the Workshop
INVITED SPEAKERS
**INVITED SPEAKERS**

**PREP, GENDER ISSUES**

**Jean Anderson MD** was the founder and first director of the Johns Hopkins HIV Women’s Health Program, one of the first initiatives in the country to use peer counselors to support patients.

Dr. Anderson completed her obstetrics and gynecology internship and residency at Vanderbilt in 1983 and remained on the faculty for the next three years as an attending. In July, 1987 Dr. Anderson began work at Johns Hopkins Hospital in Baltimore, Maryland, as an assistant professor of gynecology and obstetrics.

Dr. Anderson helped establish the Johns Hopkins HIV Women’s Health Program, and she continues to serve as its director. Providing comprehensive care to women with HIV, Dr. Anderson’s program was among the first to use peer counselors to support patients and help women manage their treatment regimen. This is especially useful now that pregnant women can prevent the transmission of the virus during pregnancy and labor with the appropriate medical care, and that all patients can stay healthy through the use of combination drug therapies.

Dr. Anderson has developed a national and international reputation as a leader in the specialty. Dr. Anderson still finds her greatest satisfaction in day-to-day interaction with patients and medical students, and is especially proud of the four teaching awards she has received since joining the faculty at Hopkins. She is a fellow of the American College of Obstetricians and Gynecologists and a member of the American Academy of HIV Medicine.

**CURE – EARLY DETECTION AND EARLY TREATMENT**

**Merlin Robb MD** is the Deputy Director for Clinical Research for the U.S. Military HIV Research Program (MHRP). He is a board certified pediatric infectious disease specialist with research experience in molecular biology, neutralizing antibody assay development, perinatal and pediatric HIV research, HIV correlates of protection research, acute infection studies, HIV immuno-therapeutic trials, the design and conduct of Phase I, II and III clinical trials and the strategic planning and organization of vaccine development programs for East Africa.

Dr. Robb was instrumental in developing MHRP’s global research infrastructure in Uganda, Kenya, Tanzania, Nigeria, Mozambique and Thailand.

Dr. Robb has contributed to HIV vaccine prevention and therapy research since 1992 to include the first study to show protection from infection with an HIV vaccine, the recently completed phase III HIV vaccine trial in Thailand, also known as RV144.

Dr. Robb joined MHRP in 1990 while on active duty in the US Army and is currently employed by the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF), and serves as the HJF director for MHRP. MHRP is a collaboration between HJF and the Walter Reed Army Institute of Research (WRAIR) Division of Retrovirology.
MODELS OF CARE – THE US SITUATION

Jennifer Kates PhD is Vice President and Director of Global Health & HIV Policy at the Kaiser Family Foundation. She oversees the Foundation’s policy analysis and research focused on the U.S. government’s role in global health and on the global and domestic HIV epidemics. Widely regarded as an expert in the field, she regularly publishes and presents on global health and HIV policy issues and is particularly known for her work analyzing donor government investments in global health; assessing and mapping the U.S. government’s global health architecture, programs, and funding; and tracking and analyzing major U.S. HIV programs and financing, and key trends in the HIV epidemic, an area she has been working in for twenty-five years.

Dr. Kates serves on numerous federal and private sector advisory committees on global health and HIV/AIDS issues. Currently, she is a Member of the CDC/HRSA Advisory Committee on HIV and STD Prevention and Treatment (CHAC). She recently served on the Institute of Medicine’s (IOM) Congressionally-mandated evaluation of the President’s Emergency Plan for AIDS Relief (PEPFAR), and on two IOM study committees commissioned by the White House to inform the implementation of the National HIV/AIDS Strategy.

Dr. Kates received her Ph.D. in Health Policy from George Washington University, where she is also a lecturer. She holds a Bachelor’s degree from Dartmouth College, a Master’s degree in Public Affairs from Princeton University’s Woodrow Wilson School of Public and International Affairs and a Master’s degree in Political Science from the University of Massachusetts.

MODELS OF CARE – THE UK/EUROPEAN SITUATION

Margaret Johnson MD, FRCP is the clinical director of the Royal Free Centre for HIV medicine and is Professor of HIV Medicine at University College London. She has been involved in the management of women with HIV infection since 1989 when she was appointed the first HIV physician in the UK.

One of her first projects on appointment was the development of a designated HIV clinic for women. More recently she chaired the British HIV Association from 2004 to 2008. Together with Professor Jane Anderson she has chaired BHIVA guidelines for the management of women with HIV.
MODELS OF CARE – THE RLS SITUATION

Kogieleum Naidoo MD is head of the Treatment Research Program at the Centre of the AIDS Program of Research in South Africa (CAPRISA). She is the lead investigator in CAPRISA studies aimed at optimizing treatment strategies for TB-HIV co-infected patients; leads all Adult AIDS Clinical trial Group (ACTG) network trials undertaken by CAPRISA; and is co-Principal Investigator on the PEPFAR funded Durban and Vulindlela CAPRISA AIDS Treatment Program.

Dr Naidoo is currently the PI of the CAPRISA study on TB recurrence in TB-HIV co-infected patients, previously successfully treated for TB. Her most significant scientific contribution is the CAPRISA SAPiT trial, which served as the basis for the 2009 WHO Rapid Advice on TB-HIV treatment integration. These findings were subsequently incorporated into the WHO international guidelines, the US government DHHS guidelines and the South African guidelines for treatment of TB-HIV co-infected individuals.

She is an Advisor, guiding policy on TB-HIV service integration in KwaZulu-Natal. Her research on immune reconstitution inflammatory syndrome and rifampicin-efavirenz drug interactions has been influential in defining treatment strategies for these two common complications of integrating TB-HIV treatment. She serves as a reviewer for several leading journals and was awarded the Fogarty Ellison Research Scholarship in Global Health in 2005.

CONCEPTION AND HIV

Fiona Lyons MD is a consultant in Genitourinary and HIV Medicine at the GUIDE clinic, St. James’s Hospital, Dublin, Ireland (www.guideclinic.ie). The GUIDE clinic is the largest adult HIV and STI service in the Republic of Ireland.

Dr. Lyons qualified from Trinity College Dublin in 1992. She worked for many years in obstetrics and gynaecology and completed her post graduate training in Genitourinary and HIV medicine in 2004. Following completion of her post graduate training she took up her first consultant post in St. Thomas’s Hospital, London where she established and was clinical lead for a contraception service for HIV infected women and joint clinical lead for the management of HIV infected women in pregnancy.

Dr. Lyons returned to Ireland in 2007 to take up her current post. She is lead author on the Irish guidelines for the management of HIV in pregnancy and joint clinical lead for the management of HIV serodiscordant couples wishing to conceive and HIV infected women in pregnancy. Since taking up her current post in 2007, Dr. Lyons has established an inreach Genitourinary and HIV medicine service in two of Dublin’s male prisons.
HIV, ONCOGENIC HPV, AND PREVENTION METHODS

Aron Tobian MD, PhD is an Associate Professor of Pathology, Medicine and Epidemiology at The Johns Hopkins University School of Medicine and Bloomberg School of Public Health. He is also an Associate Medical Director of Transfusion Medicine at Johns Hopkins Hospital and Investigator with the Rakai Health Sciences Program in Uganda. Dr. Tobian completed a combined MD/PhD program at Case Western Reserve University. During medical school, he was elected into the Alpha Omega Alpha (AOA) Honor Medical Society. He completed a clinical pathology residency and transfusion medicine fellowship at Johns Hopkins Hospital and subsequently joined the faculty at Johns Hopkins University. Dr. Tobian has collaborated with the Rakai Health Sciences Program and established a research program evaluating the epidemiologic risk factors of HIV and other sexually transmitted infections. Dr. Tobian has evaluated the efficacy of male circumcision to prevent sexually transmitted infections, including human papillomavirus, in men and their female partners. Dr. Tobian has also assessed the risk factors of human papillomavirus acquisition and clearance and the role of human papillomavirus infection and its association with HIV acquisition.

OSTEOPORIS IN ELDERLY HIV INFECTED PATIENTS

Savannah Cardew MD, FRCP(C) is a general internist and clinical associate at the University Health Network and Women’s College Hospital in Toronto Ontario. She received her medical training and the University of British Columbia and the University of Toronto. In addition to general internal medicine, her primary outpatient focus is osteoporosis and bone densitometry. She has a particular interest in the investigation and treatment of bone health issues in younger women and men. Most osteoporosis outreach and education focuses on postmenopausal women. She is working on completing a master’s in clinical epidemiology, investigating predictors of bone density decline in women taking aromatase inhibitors for breast cancer prevention.

EPIDEMIOLOGY OF HCV CO-INFECTION

Shruti Mehta PhD, MPH is an Associate Professor of Epidemiology and the Director of the Infectious Diseases Area of Concentration at the Johns Hopkins Bloomberg School of Public Health. She received her PhD and MPH from the Johns Hopkins Bloomberg School of Public Health. Her research encompasses HIV and hepatitis C virus among injection drug using populations, with a particular focus on improving access to care and treatment for HIV and hepatitis C. She leads a longitudinal cohort of IDUs in Baltimore, the ALIVE study, as well as several studies in India focused on HIV and hepatitis C.
NEW TREATMENT OPTIONS FOR HIV/HCV CO-INFECTION

Marina Klein MD, MSc, FRCP(C) is an Associate Professor of Medicine, McGill University, Montreal, Canada in the Division of Infectious Diseases/Chronic Viral Illnesses. She graduated from McGill Medical School (1991) and received her training in Internal Medicine at the Royal Victoria Hospital in Montreal. She completed a research fellowship in Infectious Diseases at the University of Minnesota in 1998 and then returned to McGill University where she received a Master’s degree in Epidemiology and Biostatistics (2003).

Her clinical interests focus on treatment of patients with HIV and chronic viral hepatitis. She is a prominent researcher in clinical and epidemiologic aspects of HIV and Hepatitis C co-infection and leads a Canadian Institutes of Health Research funded prospective cohort study of over 1000 HIV-HCV co-infected patients to study the interaction of these chronic viral infections. She has also been a principal investigator in several clinical trials of HIV-HCV co-infection.

She is also involved in a number of observational epidemiologic research collaborations (e.g. NA-ACCORD and CANOC) focused on understanding longterm clinical and treatment outcomes in HIV and in HIV-HCV co-infection where she has assumed a leadership role in scientific steering committees. She was elected to the IAS Governing Council in 2012 representing the North American Region.

STATE-OF-THE-ART LECTURE ON NEW THERAPY OPTIONS

Sharon Walmsley FRCPC, MD, MSc is Director of Clinical Research, Immunodeficiency Clinic, Toronto Hospital, University Health Network and a Professor, University of Toronto Department of Medicine.

She received her MD from the University of Western Ontario, and a Master’s degree in Clinical Epidemiology at the University of Toronto.

Dr. Walmsley has been actively involved in the design and conduct of many clinical trials, including trials in HIV therapy; prophylaxis and treatment of opportunistic infections, and management of the complications of treatment. Her current research interests involve the interaction between HIV and herpes virus co-infection.

Dr. Walmsley also has a strong interest in HIV in women, and is a co-investigator of the Canadian Women’s HIV Study group which is currently evaluating the HPV vaccine in HIV infected women and girls. She has numerous peer-reviewed publications and research awards and is the recipient of a Career Scientist Award from the Ontario HIV Treatment Network. She is the Elected National Chair of the Steering committee and co-chair of the Clinical Management Core of the Canadian HIV Trials Network.
OUR NAME IS NEW.
OUR COMMITMENT TO HEALTHCARE WILL NEED NO INTRODUCTION.

Few enterprises arrive in the world as ready to serve patients as AbbVie. We are a new biopharmaceutical company, emerging from Abbott with a 125-year history of patient care.

To advance global healthcare, AbbVie unites the expertise and stability of a successful pharmaceutical company with the innovative scientific spirit of a biotech. Our commitment to deliver solutions that make a remarkable impact in people’s lives continues the legacy of our Abbott origins.

We’re proud to introduce ourselves as AbbVie, but we never forget that what we do is more important than what we’re named.

abbvie.com